Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond
JT Nauseef, NH Bander, ST Tagawa - European Urology Focus, 2021 - Elsevier
Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate
cancer. A variety of PSMA-based therapies, including radionuclide-and cytotoxic drug-
conjugated and cellular immune products, are in development, each with variable
advantages and disadvantages. Here we briefly describe the landscape of PSMA-based
therapies beyond 177 Lu-PSMA-617, which is covered elsewhere. Patient summary
Prostate-specific membrane antigen (PSMA) is a protein expressed on most prostate cancer …
cancer. A variety of PSMA-based therapies, including radionuclide-and cytotoxic drug-
conjugated and cellular immune products, are in development, each with variable
advantages and disadvantages. Here we briefly describe the landscape of PSMA-based
therapies beyond 177 Lu-PSMA-617, which is covered elsewhere. Patient summary
Prostate-specific membrane antigen (PSMA) is a protein expressed on most prostate cancer …